Trastuzumab Deruxtecan in HER2-Low Breast Cancer

被引：0
|
作者：
Carroll, Hailey K. [1 ]
Higgins, Michaela J. [2 ]
O'Reilly, Seamus [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
[2] St Vincents Univ Hosp, Dublin, Ireland
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1144 / 1144
页数：1
相关论文
共 50 条
  • [1] TRASTUZUMAB DERUXTECAN IS EFFECTIVE IN HER2-LOW BREAST CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (04) : 488 - 488
  • [2] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Xu, Binghe
    Wang, Xiaojia
    Gil-Gil, Miguel
    Li, Wei
    Pierga, Jean-Yves
    Im, Seock-Ah
    Moore, Halle C. F.
    Rugo, Hope S.
    Yerushalmi, Rinat
    Zagouri, Flora
    Gombos, Andrea
    Kim, Sung-Bae
    Liu, Qiang
    Luo, Ting
    Saura, Cristina
    Schmid, Peter
    Sun, Tao
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Vitazka, Patrik
    Meinhardt, Gerold
    Harbeck, Nadia
    Cameron, David A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 9 - 20
  • [3] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [4] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [5] The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer
    Schlam, Ilana
    Tolaney, Sara M.
    Tarantino, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1059 - 1066
  • [6] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [7] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [8] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
  • [9] Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
    Poumeaud, F.
    Morisseau, M.
    Cabel, L.
    Goncalves, A.
    Rivier, C.
    Tredan, O.
    Volant, E.
    Frenel, J. -s.
    Ladoire, S.
    Jacot, W.
    Jamelot, M.
    Foka Tichoue, H.
    Patsouris, A.
    Teixeira, L.
    Bidard, F. -c.
    Loirat, D.
    Brunet, M.
    Levy, C.
    Bailleux, C.
    Cabarrou, B.
    Deleuze, A.
    Uwer, L.
    Deluche, E.
    Grellety, T.
    Franchet, C.
    Fiteni, F.
    Bischoff, H.
    Vion, R.
    Pagliuca, M.
    Verret, B.
    Becourt, S.
    Reverdy, T.
    de Nonneville, A.
    Dalenc, F.
    BRITISH JOURNAL OF CANCER, 2024, 131 (04) : 702 - 708
  • [10] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
12345